StreetInsider.com News Articles

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $87 at JPMorgan

Tue, 20 Oct 2026 08:41:27 -0400

JPMorgan analyst Jessica Fye raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $87.00 (from $86.00) while maintaining a Overweight rating.

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $88 at UBS

Thu, 15 Oct 2026 09:21:56 -0400

UBS analyst Joone Lee lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $88.00 (from $114.00) while maintaining a Buy rating.

BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Barclays

Wed, 14 Oct 2026 04:18:50 -0400

Barclays analyst Eliana Merle raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $114.00 (from $111.00) while maintaining a Overweight rating.

Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy

Mon, 12 Oct 2026 05:06:19 -0400

(Updated - October 12, 2026 5:06 AM EDT)

Raymond James analyst Chris Raymond upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Strong Buy with a price target of $109.00.

The analyst comments "Moving to Strong Buy on BMRN shares after hosting investor meetings with management for two days last week in Boston/New York. With shares having essentially round-tripped (from mid-$50s to $70, back to the mid-$50s) since our May 21 valuation call, we note that BMRN is now trading at ~2X 2027E revenue and ~8X 2027E non-GAAP EPS, despite our expectations of revenue CAGR of 10% and non-GAAP EPS CAGR of

Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy

Mon, 12 Oct 2026 05:06:19 -0400

(Updated - October 12, 2026 5:06 AM EDT)

Raymond James analyst Chris Raymond upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Strong Buy with a price target of $109.00.

Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy

Mon, 12 Oct 2026 05:06:19 -0400

(Updated - October 12, 2026 5:06 AM EDT)

Raymond James analyst Chris Raymond upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Strong Buy with a price target of $109.00.

Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy

Mon, 12 Oct 2026 05:06:19 -0400

(Updated - October 12, 2026 5:06 AM EDT)

Raymond James analyst Chris Raymond upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from Outperform to Strong Buy with a price target of $109.00.

BioMarin presents Voxzogo skeletal dysplasia data at ASBMR meeting

Fri, 09 Oct 2026 09:05:46 -0400

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) presented data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting in Boston, including results from studies of Voxzogo (vosoritide) in children with achondroplasia and hypochondroplasia.

Key data included a post-hoc analysis from a randomized, double-blind, placebo-controlled trial evaluating Voxzogo's effect on the growth of the foramen magnum and craniocervical junction in children with achondroplasia, including infants. Those regions of the skull are associated with cervicomedullary compression and related complications in achondroplasia patients.

Additional presentations covered bone strength, limb alignment, and data on the investigational long-acting medicine BMN 333. Phase 3

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

Fri, 09 Oct 2026 09:05:00 -0400

New analysis showcases impact of VOXZOGO^® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants

SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

Fri, 09 Oct 2026 09:05:00 -0400

New analysis showcases impact of VOXZOGO^® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants

Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 06

Tue, 06 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261006/27155809.html

BioMarin names Cara Bauer as chief people officer

Mon, 05 Oct 2026 16:06:54 -0400

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Cara Bauer, Ph.D., as Executive Vice President and Chief People Officer, effective Oct. 5, 2026, according to a press release from the San Rafael, California-based company.

Bauer succeeds Amy Wireman, who is retiring after joining BioMarin in 2013 and serving as Chief People Officer since 2019. Wireman will remain at the company in an advisory capacity during the transition.

Bauer joins BioMarin from Kyverna Therapeutics, Inc., where she served as Chief Human Resources Officer. Before joining Kyverna in October 2024, she was global head of human resources at Kite, a Gilead company. Earlier in her

BioMarin Appoints Cara Bauer as Chief People Officer

Mon, 05 Oct 2026 16:05:00 -0400

Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries

Appointment Effective Oct. 5, 2026

SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D., has been named

BioMarin Appoints Cara Bauer as Chief People Officer

Mon, 05 Oct 2026 16:05:00 -0400

Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries

Appointment Effective Oct. 5, 2026

SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D., has been named

BioMarin shares five-year Pompe disease drug data at muscle congress

Fri, 02 Oct 2026 11:00:20 -0400

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) presented five-year Phase 3 open-label extension data for its two-drug combination Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) in late-onset Pompe disease at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan.

The analysis drew from 82 individuals who received Pombiliti and Opfolda continuously from the baseline of the initial PROPEL study. The group included 62 enzyme replacement therapy (ERT)-experienced patients, whose mean prior ERT duration at baseline was 7.6 years, and 20 ERT-naïve patients.

In the ERT-experienced cohort at year five, the mean change from baseline in percent predicted six-minute walk distance (pp6MWD) was

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

Fri, 02 Oct 2026 11:00:00 -0400

Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease

SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI^® (cipaglucosidase alfa-atga) + OPFOLDA^® (miglustat) in late-onset Pompe disease (LOPD) were presented at the 31st Annual Congress of the World Muscle Society

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

Fri, 02 Oct 2026 11:00:00 -0400

Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease

Form 4 BIOMARIN PHARMACEUTICAL For: Sep 30 Filed by: Friberg Gregory R

Thu, 01 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261001/27136305.html

Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 24

Wed, 30 Sep 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260930/27128849.html

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital

Wed, 16 Sep 2026 08:41:40 -0400

(Updated - September 16, 2026 8:41 AM EDT)

BMO Capital analyst David Lebowitz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $97.00 (from $98.00) while maintaining a Outperform rating.

The analyst commented: "Noonan Exit Sharpens Voxzogo Focus on HCH/ISS With Limited Impact; BioMarin discontinued development of Voxzogo in Noonan syndrome, sharpening its focus on larger expansion opportunities in HCH and ISS. The decision to discontinue the Phase 2 Noonan study was unrelated to the safety or efficacy profile of Voxzogo. Relatively small addressable population of NS provides modest peak-sales opportunity, and impact from the discontinuation is therefore limited. We

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital

Wed, 16 Sep 2026 08:41:40 -0400

(Updated - September 16, 2026 8:41 AM EDT)

BMO Capital analyst David Lebowitz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $97.00 (from $98.00) while maintaining a Outperform rating.

BioMarin drops VOXZOGO development for Noonan syndrome children

Tue, 15 Sep 2026 08:34:15 -0400

BioMarin Pharmaceutical Inc. announced on September 15, 2026, that it will discontinue development of VOXZOGO for children with Noonan syndrome.

According to a company statement, the decision was based on an assessment of factors including study feasibility and the current treatment landscape for children with Noonan syndrome. BioMarin stated the decision was not related to the safety or efficacy of VOXZOGO.

BioMarin drops VOXZOGO development for Noonan syndrome children

Tue, 15 Sep 2026 08:34:15 -0400

BioMarin Pharmaceutical Inc. announced on September 15, 2026, that it will discontinue development of VOXZOGO for children with Noonan syndrome.

BioMarin drops VOXZOGO development for Noonan syndrome children

Tue, 15 Sep 2026 08:34:15 -0400

BioMarin Pharmaceutical Inc. announced on September 15, 2026, that it will discontinue development of VOXZOGO for children with Noonan syndrome.

BioMarin drops VOXZOGO development for Noonan syndrome children

Tue, 15 Sep 2026 08:34:15 -0400

BioMarin Pharmaceutical Inc. announced on September 15, 2026, that it will discontinue development of VOXZOGO for children with Noonan syndrome.